2022 World Conference on Lung Cancer (ePosters)-EP08.01-013. Ramucirumab plus Atezolizumab in Patients with Stage IV NSCLC Previously Treated with Immune Checkpoint Blockade

EP08.01-013. Ramucirumab plus Atezolizumab in Patients with Stage IV NSCLC Previously Treated with Immune Checkpoint Blockade

Back to course

Pdf Summary

A phase II study was conducted to evaluate the combination of Ramucirumab and Atezolizumab in patients with non-small cell lung cancer (NSCLC) who had previously received immune checkpoint blockade therapy. The study included 21 patients in two stages. The primary endpoint was overall response rate (ORR), and secondary endpoints included clinical benefit rate, progression-free survival (PFS), overall survival (OS), and adverse events.<br /><br />The results showed that the combination treatment did not meet the primary endpoint, with an ORR of 4.8%. The median PFS was 3.4 months, and nine patients received subsequent therapy. The median OS was 16.5 months. Safety analysis demonstrated that the combination had a safety profile consistent with the individual agents.<br /><br />Exploratory endpoints included deep profiling of phenotypic and functional markers on immune cells using mass cytometry. These analyses are ongoing.<br /><br />The patient demographics showed a median age of 67, with a majority of female patients. The histology was predominantly non-squamous, and the expression of PD-L1 varied. The patients had previously received a median of three systemic lines of therapy and one line of immune checkpoint inhibitors.<br /><br />Grade 3 or greater adverse events were reported, with hypertension being the most common. There were no grade 5 adverse events, and some adverse events led to discontinuation of therapy.<br /><br />In conclusion, the combination of Ramucirumab and Atezolizumab did not demonstrate a significant overall response rate in NSCLC patients who had received previous immune checkpoint blockade therapy. However, further analyses and exploratory endpoints are ongoing. The safety profile of the combination was consistent with the individual agents.

Asset Subtitle

Brett Howard Herzog

Meta Tag

Speaker Brett Howard Herzog

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

Ramucirumab

Atezolizumab

non-small cell lung cancer

NSCLC

immune checkpoint blockade therapy

overall response rate

clinical benefit rate

progression-free survival

overall survival

adverse events